The role of p53 inactivation in human cervical cell carcinoma development. by Miwa, K. et al.
MUish Jor dCano (195) 71,219-226
© 1995 Stadto Press Al rThts rrved 0007-0920/95 $9.00 x
The role of p53 inactivation in human cervical cell carcinoma
development
K Miwal2, S Miyamoto2, H Kato2, T Imamura2, M Nishida2, Y Yoshikawa3, Y Nagatal and
N Wake2
'Department ofObstetrics and Gynecology, Facultt ofMedicine, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890,
Japan; 2Departments ofReproductive Physiology and Endocrinology and 3Department ofInspection, Medical Institute of
Bioregulation, Kvushu University, 4546, Tsurumihara, Beppu, 874, Japan.
Smnumry We investigated the association between human papillomavirus (HPV) infection and p53 gene
mutation in 47 primary uterine cervical cancers. HPV DNA sequences were present in 43 cancers (91.5%), and
one of these cancers contained a p53 gene mutation. In addition, one of the remaining four HPV-negative
cancers also contained a p53 gene mutation. As a result, p53 inactivation corresponded to the development of
44 of the primary uterine cervical cancers studied (93.6%). We obtained both primary and recurrent tumours
from four cases. In two of these cases, the HPV genomes that were present in an episomal state in the primary
tumours were observed to have disappeared in the recurrent tumours. One of these recurrent tumours also
contained a p53 gene mutation, which suggested the possibility that p53 inactivation was required in order to
maintain the aggressive behaviour in this cancer either by an HPV infection or by a p53 gene mutation. No
MDM2 gene amplification was observed in the tumours that carried neither HPV DNAs nor p53 gene
mutations.
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Uterine cervical cancer is the most common genital malig-
nancy, and a strong association with human papillomaviruses
(HPVs) has been suggested (zur Hausen, 1987). More than 65
different types of HPVs have been described. A subgroup of
these viruses, including HPV types 16, 18, 31, 33, 52b and 58,
has been aetiologically implicated in cervical cell carcino-
genesis (Fujinaga et al., 1991) because they are found in a
high percentage of these cancers and because benign lesions,
with which these viruses are usually associated, are con-
sidered to be precursors for malignant progression. Only part
of the HPV genome, encoding the E6 and E7 proteins, is
consistently retained and expressed in cancer cells. The coor-
dinated expression of E6 and E7 has been shown to contri-
bute to the transformation of rodent cells and the immorta-
lisation of primary human keratinocytes (Bedell et al., 1989;
Muinger et al., 1989; Barbosa et al., 1991). One important
function of the E6 oncoprotein is its ability to form a com-
plex with the cellular p53 protein (Werness et al., 1990),
resulting in an ubiquitin-dependent degradation of the latter
protein. Likewise, the E7 oncoprotein also forms a complex
with the cell-encoded retinoblastoma protein (pRb) (Dyson et
al., 1989).
Mutations in the p53 gene are frequently observed in a
wide vanrety of human malignancies (Hollstein et al., 1991).
It is thus conceivable that an abrogation of p53 gene func-
tions could be implicated in the aetiology of cancers. Such
p53 gene mutations have also been documented in cervical
cancers and their cell lines. Only HPV-negative cervical
cancers carry p53 mutations (Crook et al., 1992), an observa-
tion compatible with the assumption that the abrogation of
the p53 gene functions is caused either by binding with the
HPV E6-encoded protein or by a mutation associated with
cervical cell carcinogenesis (Crook et al., 1991; Scheffner et
al., 1991). However, this hypothesis still remains inconclusive
because the p53 inactivation may not be obligatory for a few
HPV-negative cancers (Fujita et al., 1992). Several possi-
bilities have to be considered in the development of cancers
that carry neither the HPV genome nor a p53 gene mutation.
First, HPV DNAs or p53 gene mutations could exist but
could simply be undetectable by standard methods. Second,
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mutations could exist in other genes that interact with p53 or
downstream of p53 and thus result in an identical physio-
logical defect within the cell. Third, mutations in other genes,
which are totally unrelated to p53, could occur in some
cancers, resulting in a transformation process that is quali-
titatively different from HPV-mediated carcinogenesis. Thus,
the present study was undertaken to define the molecular
mechanism associated with HPV-negative cancer develop-
ment.
The polymerase chain reaction (PCR) and subsequent
restriction enzyme typing are sufficiently sensitive to detect a
subgroup of HPVs associated with cervical cancer. Both a
sense primer, pU-lM, that is homologous to a region in the
E6 open reading frame (ORF) and an antisense primer,
pU-2R, that is homologous to a region in the E7 ORF were
used for amplification. This method is also useful in identify-
ing potentially new HPV types (Fujinaga et al., 1991).
Southern blot hybridisation in conjunction with polymerase
chain reaction (PCR) was able to detect lo-5 to 106 copies
of the HPV genome per cell, which was sufficient to deter-
mine the presence of HPVs (Roman and Fife, 1989). We thus
studied the frequency of HPV infection in 51 cervical cancers
that involved both primary and recurrent tumours, and
found four primary and two recurrent tumours that were
HPV negative. The p53 gene mutation was recognised in 1 of
the 45 HPV-positive tumours and in two of six HPV-negative
tumours. The HPV genomes that were present as episomes in
two primary cancers were observed to have disappeared in
the recurrent tumours, and thus suggested the possible route
of HPV-negative cancer development.
The disappearance of the HPV genome was followed by
the appearance of a new p53 mutation in one of these two
recurrent tumours. These findings might thus imply both p53
inactivation in the initiation of cervical cell carcinogenesis
and the maintenance of transformed properties even if the
frequency of p53 mutation was low in HPV-negative
cancers.
The closest analogue to the interaction between E6 and
p53 in cervical cancers is provided by the murine double
minute 2 (MDM2) genes and p53 in sarcomas. An MDM2
gene product which binds to p53 has been shown to be
amplified in a subset of sarcomas (Oliner et al., 1992). If a
major effect of MDM2 gene amplification were inactivation
of the p53 protein, then cervical cancers with the MDM2p53 Inaivadon in cervl cc developneit
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gene amplification, which are devoid of both HPV DNAs
and p53 mutations, would be expected. However, no MDM2
gene amplification was associated with the four cancers that
carried neither HPV DNAs nor p53 gene mutations.
Materials and methods
Samples and DNA extraction
Samples for this study were obtained from 51 patients with
47 primary and four recurrent uterine cervical cancers who
underwent a biopsy at the Department of Obstetrics and
Gynecology. Medical Institute of Bioregulation, Kyushu
University. All specimens had been fixed in 10% neutral
formalin and embedded in paraffin. The tumours were histo-
logically classified according to the WHO histological typing
system. The clinical stage of the disease was based on the
International Federation of Gynecology and Obstetrics stag-
ing system. Genomic DNA was extracted from formalin-fixed
and paraffin-embedded tissue samples using previously des-
cribed procedures (Goelz et al.. 1985).
Detection and tiping ofHPV DNA
The detection and typing of HPV DNA were performed
using the polymerase chain reaction (PCR) as previously
described (Fujinaga et al.. 1991). Briefly. the reaction mixture
of PCR contained 1.0 iLg of DNA. 100 pmol of each consen-
sus primer (pU-lM. 5'-TGTCAAAAACCGTTGTGTCC-3';
pU-2R. 5'-GAGCTGTCGCTTAATTGCTC-3') 200gM of
each dNTP. 50 mM potassium chloride. 10 mM Tris-HCI
pH 8.3. 1.5 mM-magnesium chloride. 100jg ml- ' gelatin and
2.5 units of Taq DNA polymerase in a total volume of
100fil. One cycle of PCR consisted of denaturation (94'C for
1 min), primer annealing (55'C for 2 min) and extension
(72'C for 2 mmn) for 30 cycles (Thermo Cycler; Perkin-Elmer
Cetus). The PCR product (10 gil) was electrophoresed on 2%
agarose gel and stained with ethidium bromide and photo-
graphed under UV light. For the typing of HPV DNA. the
residual PCR product was digested with restriction enzymes
(Avall, RsaI, BglIl and AccI) and the digested products were
then analysed on 2% agarose gel. The PCR products in
which no HPV DNA was detected by the previous method
were then further examined for the presence of HPV-16 or
-18 using Southern blot hybridisation. They were electro-
phoresed on 1.5% agarose gel and denatured in a denaturing
solution (1.5 M sodium chloride, 0.5 M sodium hydroxide)
and neutralised in a neutralising solution (1.5 M sodium
chloride. 0.5 M Tris-HCI pH 7.2. 0.001 M EDTA), and then
were transferred to a nylon membrane (Hybond -N+, Amer-
sham). Prehybridisation was carried out in 5 x SSPE,
5 x Denhardt's solution, 0.5% SDS and 100gigml-'
denatured salmon sperm overnight at 65'C. Hybnrdisation
was done for 12 -24 h at 65'C in the same solution as used
for prehybnrdisation with 3'P-labelled probes. using a
random-pnrmer method. HPV-16 and -18 probes were syn-
thesised by PCR using DNA denrved from SiHa (HPV-16)
and HeLa (HPV-18) cells respectively. as descnrbed above.
The membranes were washed tWice in 2 x SSPE. 0.1% SDS.
at room temperature for 10 min, once in 1 x SSPE. 0.1I%
SDS. at 65'C for 15 min. and if necessary once in 0.1%
SSPE. 0.10% SDS. at 65'C for 10 min. and then autoradiog-
raphed.
PCR -single-strand conformation polv morhism (SSCP}
analy sis
PCR-SSCP analysis was performed to detect mutations of
the p53 gene as described previously (Hayashi et al.. 1989:
Murakami et al.. 1991; Kishimoto et al., 1992). The primers
for the PCR were designed to produce the DNA fragments
which covered the entire coding region (from codon 1 to
codon 393) of the p53 gene (shown in Table I). Aliquots of
0.1 gLg of DNA were subjected to the PCR. using 32P- end-
labelled primers. One PCR cycle consists of denaturation
(95°C for 1 min), primer annealing (55°C for 2 min) and
extension (72'C for 2 min) for 30 cycles. The PCR product
was diluted with a loading solution (95% formamide. 20 mM
EDTA. 0.05% xylene cyanol. 0.05% bromphenol blue) and
was denatured at 80'C. and then applied to 5% non-denatur-
ing acrylamide gel (acrylamide-methylene-bis acrylamde.
99:1). either with or without 5% glycerol. Electrophoresis
was performed at 40 W for 4-7 h while being cooled with a
fan. The gel was dried on filter paper and exposed to X-ray
film at room temperature for 1 - 12 h with an intensifying
screen.
Cloning and sequencing
Fragment F from codon 262 to codon 331 of the p53 gene
which showed a mobility shift in the PCR-SSCP analysis
was sequenced to confirm and localise any point mutations.
Since the primers used for the PCR-SSCP analysis had no
extraneous nucleotides including any restriction of the
enzyme-cut site. new primers, which had extraneous
nucleotides including EcoRI and HindIII sites, where used for
PCR in fragment F (Fl, 5'-CGAATTCTGAGTAGTGGT-
AATCT-3'; F2, 5'-CCCAAGCTTTAGTACCTGAAGGGT-
3'). PCR products were purified, digested with EcoRI and
HindlII. and ligated into the EcoRI and HindIII sites of
pUC18 plasmid. Sequencing was performed by the dideoxy
sequencing reaction with BcaBEST DNA polymerase (TaKa-
Ra), using fluorescein isothiocyanate (FITC)-labelled primers
(FITC primer M4, 5'-CGCCAGGGTTT`TCCCAGTCAC-
GAC-3'; FITC primer RV-M. 5'-GAGCGGATAACAATT-
TCACACAGG-3'; TaKaRa).
Table I Primers used for the amplification of the p53 gene
Amplified DNAfragment Primer
Name Region Codon Length (bp} Name Sequence
A Exons 2-3 1-32 185 Al 5'-TGGAT CCTCT TGCAG CAGCC-3'
A2 5'-AACCC TTGTC CTITAC CAGAA-3'
B Exon 4 33-125 293 Bi 5'-ATCTA CAGTC CCCCT TGCCG-3'
B2 5'-GCAAC TGACC GTGCA AGTCA-3'
C Exons 5-6 126-201 325 Cl 5'-TTCCT CTTICC TGCAG TACTC-3'
C2 5'-GCAAA T1TCC TTCCA CTCGG-3'
D Exons 5 -6 179-224 236 Dl 5'-ACCAT GAGCG CTGCT CAGAT-3'
D2 5'-AGTTG CAAAC CAGAC CTCAG-3'
E Exon 7 225-261 139 El 5'-GTGTT GTCTC CTAGG TTGGC-3'
E2 5'-CAAGT GGCTC CTGAC CTGGA-3'
F Exons 8-9 262-331 330 Fl 5'-CCTAT CCTGA GTAGT GGTAA-3'
F2 5'-CCAAG ACTTA GTACC TGAAG-3'
G Exon 10 332-367 139 GI 5'-TGTTG CTGCA GATCC GTGGG-3'
G2 5'-GAGGT CACTC ACCTG GAGTG-3'
H Exon I1 368-393 202 HI 5'-TCTCC TACAGCCACC TGAAG-3'
H2 5'-CTGAC GCACA CCTAT TGCAA-3'p53 Intactivaion in cervial c a d opm
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Gel electrophoresis, data collection and analysis were per-
formed using a DSQ-1 DNA sequencer (Shimadzu). A mini-
mum of ten individual clones were sequenced for each speci-
men. Each sequencing reaction was performed twice, and in
each case the presence of the mutation was confirmed.
Two-dimensional gel electrophoresis and Southern blot
hv bridisation
Two-dimensional gel electrophoresis and Southern blot hyb-
ridisation, using either HPV-16 or -18 DNA as a probe, were
performed to confirm the physical states of HPV DNA in
two primary tumours (cases 44 and 46, Table II) in which
HPV DNA was present in the primary sample but absent
from the recurrent sample. A 5pg aliquot of each DNA
specimen was digested with restriction endonuclease HindlII
not cleaving within the HPV-16 and -18 genomes. The
digested DNA samples were electrophoresed on 0.4%
agarose gel at 50 V for 5 h in the first dimension and then
electrophoresed on 1.0% agarose gel at 50 V for 5 h in the
Table I1 The status of HPV prevalence, p53 expression and p53
gene
p53
HPV expressio?
16 -
16 -
18+58 -
16 +
52b +
16 -
16 -
18 -
16 -
_ ++
16 +
16 6
16 6
18 _
18 _
16 +
16 6
52b +
31 _
58 -
16 6
16 6
18+58 -
16 -
iknown +
16 +
58 -
16 -
18 -
31 _
16 6
_ +
16 +
16 +
known +
16 6
16 6
58 -
52b -
16 6
16 6
18 _
16 6
16 6
16 6
_ +
31 _
31 _
p53 gene
(codon) n
wt
wt
wt
wt
wt
wt
AAA+AGA(292)
wt
wt
AGC-*ACC(269)
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
wt
WI
WI
WI
WI
GCT->TGT(273)
wt
wt
second dimension. The procedures of denatunrng, neutralisa-
tion, transferring, prehybridisation, hybridisation and
washing were all performed as described above.
Immunohistochemistrv
Immunohistochemical detection was performed using the
anti-p53 mouse monoclonal antibody DO-7 (NCL-p53-DO-7.
Novocastra Laboratories) (Vojetsek et al., 1992). Tumour
sections (5prm) from the paraffin blocks were dewaxed in
xylene and passed through alcohol and then washed in
phosphate-buffered saline (PBS). Endogenous peroxidase
activity was blocked by immersing the sections for 20 min in
methanol containing 0.3% hydrogen peroxide.
The sections were incubated with normal goat serum for
20 min at room temperature to reduce the background stain-
ing caused by non-specific binding. Primary antibody DO-7,
diluted in 1:100 in PBS, was then applied to each section.
Bound primary antibody was detected using the strepta-
vidin-biotin-peroxidase system (Dako LSAB kit, Dako)
according to the manufacturer's recommendations. A known
immunopositive case of human endometrial cancer which
demonstrated the p53 mutation was used as a positive con-
trol, and normal uterine cervical tissue was used as a negative
control. The slides received a methvl green counterstain and
were dehydrated in alcohol and xylene before mounting.
Only the tumours which exhibited intense nuclear staining
throughout the malignant epithelium were categorised as
positive cases. The staining intensity was graded as 2 + in
more than 50% of the cells, while it was 1+ in less than
50% of the cells.
PCR and Southern blot hvbridisation ofMDM2 gene
MDM2 gene amplification in four samples that carried
neither HPV DNAs nor p53 gene mutations was examined
by using PCR and Southern blot hybridisation. The primers
for PCR of the MDM2 gene were designed to produce the
DNA fragment (201 bp) which spanned nucleotides 1587-
1787 of the published MDM2 cDNA sequence (Oliner et al.,
1992) (MI, 5'-GTGGAATCTAGTFTITGCCCCTT-3'; M2, 5'-
CTAGGGGAAATAAGTTAGCAC-3'). As a reference for
the assessment of MDM2 gene amplification, the primers for
PCR of phenylalanine hydroxylase (PAH) gene, which was
also located on chromosome 12q, were designed to produce
the DNA fragment (213 bp) which spanned exon 7 to part of
intron 7 of PAH DNA sequence (Dworniczak et al.. 1990)
(AP237, 5'-CCCAAACCTCATCTT`- GCAGCA-3'; AP333,
5'-CTTGCACTGGT-TTCCGCCTC-3'). Two oligonucleotide
probes were synthesised by a Cyclone Plus DNA synthesiser
(MilliGen Biosearch, Burlington, MA, USA) and were then
used for hybridisation. The 50 bp MDM2 probe spanned
nucleotides 1591 -1640 of the published MDM2 cDNA
sequence (5'-AATCTAGTTTGCCCCTTAATGCCATTGA-
ACCTTGTGTGATTTGTCAAGGT-3'). The 50 bp PAH
probe spanned nucleotides 932-981 of the published PAH
cDNA sequence (Kwok et al., 1985) (5'-GCACTGGTlTTCC-
GCCTCCGACCTGTGGCTGGCCTGCTTTCCTCTCGG-
GAT-3'). The signal of the MDM2 probe was then compared
with that of the PAH probe. A 50 ng aliquot of DNA was
subjected to PCR. One cycle of PCR consisted of denatura-
tion (95°C for I mmn), primer annealing (55'C for 2 mmn), and
extension (72°C for 2 min), for 25 cycles (Asakawa et al.,
1992). The PCR products were electrophoresed on 1.5%
agarose gel. The procedures of denaturing, neutralisation,
transferring, prehybridisation, hybridisation and washing
were all performed as described above. The signals were also
quantitated on a BAS1000, Bio-imaging Analyzer (Fujix).
Results
Pathology and HPV infection in primary cancers
The histopathological appearance of 47 primary uterine cer-
vical cancers was squamous cell carcinoma in 42 samples
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Ta
Ta
Ta
Ta
Ta
Ib
lb
Tb
Tb
lb
Tb
Ilb
IIb
IIb
IIb
IlIb
IIb
IIb
IIIb
ITlb
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ITlb
IlIb
ITlb
Illb
ITlb
Illb
Illb
Illb
Illb
ITlb
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IITb
Illb
ITlb
Illb
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Illb
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Histology
SCC
scc
sCc
sCc
sCc
sCc
sCc
sCc
AD
sCc
SCC
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AD
sCc
SCC
SCC
SCC
SCC
SCC
scc
SCC
SCC
sCc
sCc
SCC
SCC
SCC
SCC
AD
SCC
sCc
SCC
SCC
SCC
scc
sCc
sCc
SCC
scc
SCC
scc
scc AD
SCC sCc
sCc
SCC
SCC
SCC
SCC
ADSCC
SCC
Site
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
p
R
p
R
p
R
p
R
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un
SCC, squamous cell carcinoma; AD, adenocarcinoma; AD-SCC,
adenosquamous cell carcinoma; P, pnrmary; R, recurrence; unknown,
type unknown; wt, wild type.p53 hnclaimi in a doeopind
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(89.4%), adenocarcinoma in four (8.5%) and adeno-
squamous cell carcinoma in one (2.1%). We tested the sen-
sitivity of HPV DNA detection by PCR using the pU-IM
and pU-2R primer pair. The aliquots corresponding to
1.0 x IO' to 1.0 x 10-5 copies per cell of HPV type 16 DNA
were subjected to PCR, and then the products were electro-
phoresed on 2% agarose gel. DNA fragments could be pro-
duced by PCR of an aliquot corresponding to 1.0 x 10-'
copies per cell. Aliquots in which no HPV type 16 DNA was
amplified were further analysed by Southern blot hybridisa-
tion using HPV type 16 DNA as a probe. HPV type 16 DNA
with more than I x 10-5 copies per cell could be detected by
this method (data not shown), and the findings were similar
to previous results (Roman and Fife, 1989; Fujinaga et al.,
1991). PCR of genomic DNAs with the pU-IM and pU-2R
primer pair and subsequent restriction enzyme analyses,
which were able to detect HPV types 16, 18, 31, 33, 52b and
58, as well as unknown types (Fujinaga et al., 1991), showed
that 42 out of 47 primary cancers contained HPV DNAs.
a
Case
7
Case
10
b
Codon N 7 N T
The remaining five PCR products. in which no HPV DNAs
were demonstrated, were further analysed by Southern blot
hybridisations using HPV type 16 and 18 DNAs as probes.
HPV type 16 DNA was detected in one PCR product,
although no types of HPV DNA were recognised in the
remaining four products. As a result, the HPV DNA
sequences were present in 43 out of47 primary uterine cancer
samples (91.5%), including 25 with HPV type 16 (58.1%, five
with type 18 (11.6%), three with type 31 (6.9%), three with
type 52b (6.9%) and three with type 58 (6.9%). However, the
HPV type was undetermined in two cases (4.6%) while a
mixed infection by both HPV type 18 and 58 was also
suggested in two cases (4.6%) (Table II).
The detection ofap53 gene mutation in primary- cancers
Cervical cancer DNAs were subjected to PCR-mediated
amplification of exons 2-11, which covered the entire coding
region of the p53 gene. The amplified fragments were analy-
C
Codon T 922
AAA
(Lys)
4
AGA
(Arg)
N T N Codon
N , Codon T ,m
AGC
(Ser)
I
ACC
(Thr)
Case N T Codon N 273 T Codon T273
recurrei
CGT
(Arg)
$
TGT
(Cys)
Figure 1 The detection of p53 gene mutations by both PCR- SSCP analysis and sequencing. a, PCR-SSCP analysis of the
fragment F (exons 8-9) of the p53 gene is shown. Electrophoresis was performed in 5% non-denaturing acrylamide gel containing
5% glycerol. Lane N, normal placenta; lane T, mobility shifts were displayed in three cancers: cases 7 and 10 (primary) and case
46, which demonstrated a recurrent cancer. The arrow indicates the band shift [cases 7, 10, and 46 (recurrence)]. b, Nucleotide
sequence analysis of fragment F of the p53 gene from the normal placenta. c, Nucleotide sequence analysis of fragment F of the
p53 gene from uterine cervical cancers [cases 7, 10 and 46 (recurrence)]. An AAA-*AGA transversion occurred in codon 292.
resulting in Lys+Arg substitution in case 7, an AGC+ACC transversion in codon 269, resulting in a Ser+Thr substitution in case
10 and a CGT-*TGT transversion in codon 273, resulting in an Arg+Cys substitution in case 46 (recurrence).sed by SSCP and/or sequencing to identify any abnormalities
in the p53 coding sequence. Two out of 47 primary cancer
samples showed mobility shifts of the PCR products in frag-
ment F (exons 8-9). The nucleotide sequencing confirmed
the p53 point mutation in these two tumours. One tumour
sample (case 7) had a missense point mutation of codon 292
from AAA to AGA, which resulted in a substitution of Arg
for Lys in the encoded protein. The remaining tumour (case
10) showed a point mutation involving codon 269 changing
AGC to ACC and causing a substitution of Thr for Ser in
p53Inacvation in cervicalcarcinomadevelopment
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the protein. Both wild and mutant p53 alleles were observed
in case 10, which contrasted with the finding that only one
mutant allele was recognised at this site in case 7 (Figure 1,
a MDM2 probe
1 2 3
b PAII probe
1 2
Figure 2 The physical state of HPV DNA in case 46 with a
primary cancer. A 5fig aliquot of DNA was digested with restric-
tion endonuclease HindIlI. The digested DNA was electro-
phoresed (to the right) on 0.4% agarose gel in the first dimension
and then electrophoresed (downwards) on 1.0% agarose gel in
the second dimension. Southern blot hybridisation was then per-
formed. The spot with the arrow represents the circular HPV-16
DNA. The physical state of HPV DNA was episomal in the
primary cancer of case 46.
3 4 5
Figure 4 Amplification analysis of the MDM2 gene in four
tumours (primary tumours in cases 30, 33 and 40 and a recurrent
tumour in case 44) that carried neither HPV DNAs nor p53 gene
mutations. The normal placental DNA was used as a control for
amplification. The 50 bp MDM2 probe spanned nucleotides
1591-1640 of the MDM2 cDNA sequence. The 50bp PAH
probe spanned nucleotides 932-981 of the PAH cDNA sequence.
The signal of the MDM2 probe (a) was then compared with that
of the PAH probe (b). As a result, none of the signals that
indicated the MDM2 gene amplification were shown in these four
tumours. Lane 1, normal placenta; lane 2, case 30; lane 3, case
33; lane 4, case 40; and lane 5, case 44.
a b
c d
Figure 3 Immunohistochemical detection ofp53 protein by anti-p53 mouse monoclonal antibody, DO-7. a, A uterine endometrial
cancer containing the p53 mutation is shown as a positive control. b, Normal uterine cervical tissue is also shown as a negative
control. c, Positive nuclear staining was observed in the cervical cancer specimen (case 10). d, Negative nuclear staining was
recognised in the HPV-positive cervical cancer specimen. In addition, HPV type 16 was also detected in this tumour (case 17).p53 Inctibon in cervical a n developne
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cases 7 and 10). A verification of the mutations was per-
formed by sequencing both the sense and antisense strands.
Repeated analyses of the samples demonstrated that the
mutation did not result from any infidelitv of the PCR
amplification.
We evaluated the association between the p53 mutations
and HPV infections in all 47 tumour samples. Only one (case
7) out of the 43 tumour samples that contained HPV DNAs
demonstrated a p53 mutation. However, the HPV DNA copy
number per cell of this tumour ranged from 10-1 to 1. which
was lower than that of the majority of tumours that had
contained HPV DNAs (data not shown). The remaining 42
tumour samples contained wild-type p53 genes. Among the
four tumour samples in which no HPV genomes were
demonstrated, only one tumour had a p53 mutation (case
10). As a result. two primary tumour samples that harboured
p53 mutations contained either no HPV genomes or only a
low copy number of HPV DNA per cell. These results sug-
gested that p53 inactivation corresponded to the development
of 44 primary cervical cancers (93.6%) including 42 tumours
with HPV infection, one tumour with p53 mutations and one
tumour with both an HPV infection and a p53 mutation.
However, the remaining three tumours had neither any
detectable oncogenic HPV DNAs nor mutated p53 gene
sequences (Table II).
The disappearance ofHPV DNAsfrom recurrent tumours
We obtained both primary and recurrent tumours from four
cases (cases 44. 45, 46, and 47) in order to define the role of
p53 inactivation in cervical cancer development. Primary
tumours of these four cases contained more than I x 10-'
copies per cell of HPV DNAs; HPV type 18 DNA in case 44,
type 16 in cases 45 and 46, and type 31 in case 47. However.
no DNAs could be demonstrated in the recurrent tumours of
cases 44 and 46 by Southern blot hybridisation using the
HPV type 16 or 18 DNA as a probe (Table II). HPV
genomes with more than 1.0 x 10-5 copies per cell could be
detected by this method. Two-dimensional gel electrophoresis
and Southern blot hybridisation using either HPV type 16 or
18 DNA as a probe clearly disclosed that the HPV DNA was
present in both cancer cells in an episomal state (Figure 2).
The HPV DNA types which were recognised in both primary
and recurrent tumours were identical in the remaining cases,
45 and 47 (Table II).
PCR-SSCP and sequencing of the p53 gene documented
that the recurrent tumour of case 46 contained a CGT to
TGT transversion of codon 273, which resulted in a substitu-
tion of Cys for Arg. A mutated allele alone was demon-
strated at this site [Figure 1, case 46 (recurrence)]. However,
no mobility shifts could be recognised in either case 44 with
primary and recurrent cancers or in case 46 with primary
cancer by a repeated analysis of SSCP and the sequencing of
fragment F disclosed a wild-type nucleotide sequence.
p53 protein expression
Immunohistochemical staining using the anti-p53 mouse
monoclonal antibody DO-7 was performed on 47 primary
cervical cancer samples to demonstrate further the associa-
tion between cervical cancer development and p53 inactiva-
tion. Both a normal cervical tissue specimen, which was not
immunoreactive. and an endometrial cancer specimen, which
was immunoreactive, were also subjected to staining as
negative and positive controls respectively. The cancer cell
nuclei of 12 samples showed a positive reaction (25%) even
when the nuclei of the remaining 35 samples were immuno-
negative (75%). Case 10 alone showed the intense staining
that was analogous to that of the positive control. The
remaining 11 cases showed rather weak staining localised in
the nuclei (Figure 3).
We compared the staining data with the HPV prevalence
of 47 primary and four recurrent cancer samples. Staining of
the p53 protein was demonstrated in 10 out of 45 HPV-
positive tumours. although the intensity was weak. p53 stain-
ing was absent from the remaining 35 tumours. and was
compatible with the ubiquitin-dependent degradation of p53
protein by the HPV E6-encoded protein (Huibregtse et al..
1991: Chen et al.. 1993). The HPV copy numbers per cell did
not correlate with the positivity of p53 staining in these 45
tumours. Positive staining of the p53 protein was obtained in
three of six HPV-negative tumours. Of these three, the p53-
staining positive tumours included a primary tumour in case
10. a recurrent tumour in case 46 that harboured p53 muta-
tions and a primary tumour in case 33 that contained wild-
type p53 alleles. The presence of a p53 mutation resulted in
the positive staining of the former cancers. which contrasted
with the negative staining of case 7 primary tumour carrying
the p53 mutation (Table II).
MDM2 gene amplification
The product of the MVDM2 gene appears to act as a regulator
of p53 protein function (Momand et al.. 1992). High levels of
the MDM2 gene product may thus result in a functional
inactivation of p53 protein. Hence. MDM2 gene
amplification may explain the distinct mechanism of pS3
inactivation in the particular type of cervical cancers in which
neither any oncogenic HPVs nor mutated p53 gene sequences
were detectable. MDM2 genomic DNAs were amphfied from
four tumours by PCR using the Ml and M2 primer pair.
These four tumours involved the primary tumours in cases
30. 33 and 40 and a recurrent tumour in case 44 that carried
neither HPV DNAs nor p53 gene mutations (Table II). PCR
using the AP237 and AP333 primer pair was designed to
produce an amplification of the PAH DNA sequences as a
quantitative control. However. the quantification of Southern
blot hybridisation signals by a Bio-Image Analyzer demon-
strated the absence of MD2V2 DNA amplification in these
four tumours (Figure 4).
Discussion
Evidence that the HPV E6 oncoprotein can bind p53 protein
and enhance its degradation suggests one mechanism by
which the HPV viruses could mediate transformation. In
addition, the presence of an HPV genome in a cell could
mimic the loss of the p53 function resulting from either a
deletion or a mutation. If the abrogation of p53 function is
critical to cervical cell carcinogenesis. then either HPV infec-
tion or p53 gene mutation could fulfil this requirement. Thus.
it would be of interest to define how common or rare the
genetic events that abrogate the p53 function are for this type
of cancer. A series of 47 primary and four recurrent human
cervical cancers were investigated in the present analysis. The
47 primary tumours consisted of 43 HPV-positive and four
HPV-negative tumors. Only one out of these four HPV-
negative primary tumours contained the p53 gene mutation.
whereas the remaining three all harboured wild-type p53 gene
sequences. Two of four recurrent tumours had lost the HPV
DNA even if these primary tumours contained it. One of
these two HPV-negative recurrent tumours also carried a p53
gene mutation, while the remaining one had a wild-type p53
gene sequence. As a result, it seems likely that the p53 gene
was inactivated in 47 out of 51 pnrmary and recurrent
tumours (92.1%) either by mutation in the HPV-negative
cases (two tumours) or as a consequence of the complex
formation with the HPV E6 oncoprotein (45 tumours). and
these results were consistent with the hypothesis that the p53
regulatory functions are commonly abrogated in most human
cervical cancers.
Four out of six primary and recurrent HPV-negative cer-
vical cancers contained only wild-type p53 alleles. and these
findings were consistent with previous reports in which no
HPV DNAs or p53 gene mutations were observed (Fujita et
al., 1992; Paquette et al., 1993). Since the HPV consensus
primers we used are capable of amplifying malignant HPV
DNAs efficiently. the possibility of the existence of rare HPV
types in these four tumours is quite low. If p53 inactivation is
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so critical to cervical cell carcinogenesis. why are p53 gene
mutations so rare in cases of HPV negative cervical cancer?
One possibility is that p53 in these tumours may be inactiv-
ated by some as vet unidentified or identified effector
molecules other than E6. and thus p53 gene mutations would
not be required. As a result. amplification of the MD.M12
gene. in which the product contains one effector molecule of
p53. was also investigated. However. no amplification could
be demonstrated in these HPV-negative cervical cancers. An
alternative possibility is that HPV-positive and HPV-negative
cervical cancers could represent two distinct disease entities.
The inactivation of p53 by E6 may also contribute to the
development of HPV-positive cervical cancer, but p53 may
be irrelevant to tumorigenesis of HPV-negative cervical
cancers. The data on cases 44 and 46 were used to evaluate
this alternative possibility. Both recurrent tumours lost the
HPV DNAs. which had evidently been conserved in the
primary tumours. Two-dimensional gel electrophoresis dis-
closed an episomal state of HPV DNAs in these two primary
cancers. In addition, the loss of HPV sequences had been
described in metastases of primary uterine cervical cancers
with episomal HPV 16 DNAs (Fuchs et al., 1989) and with
HPV 16 DNA (Crook and Vousden. 1992). These may also
suggest the likely path of HPV-negative tumour development.
Clonal growth of cells triggered by episomal HPVs. followed
by a positive selection for the particular cell clones that
deleted the HPVs. might also correspond to the development
of HPV-negative cancers. If this were the case. HPV DNA
that is either episomal or integrated would then be required
to initiate human keratinocyte transformation. Relevant
targets of HPVs other than p53. which involve pRB, may
also be associated with the initiation of cervical cell car-
cinogenesis.
The disappearance of HPV DNAs was accompanied by a
newly appearing p53 gene mutation in a recurrent tumour of
case 46. Although a further accumulation of data is required.
this finding may be compatible with the hypothesis that p53
inactivation through interaction with the E6 oncoprotein is
the functional equivalent of specific mutations in the p53
gene sequences. It may be possible that unidentified molec-
ular events. which are associated with the p53-regulated path-
ways, are also relevant to the particular type of cervical
cancers that carrv neither HPV DNAs nor p53 gene muta-
tions.
It is noteworthy that a mutation within the p53 gene
sequences has been documented in a stage lb cervical cancer
with low copies of HPV 16 DNA (Table II. case 7). The
mutation might confer a growth advantage and contribute to
the acquisition of invasive growth in this tumour. However,
it remains unknown whether low copies of HPV DNA
require a p53 gene mutation for the selective growth of cells
or if a p53 gene mutation is associated with the progression
of malignant phenotpes for this tumour. A previous study
suggested that the metastatic progression of HPV-positive
primary cancers was frequently accompanied by a mutation
within p53 gene sequences (Crook and Vousden, 1992).
Since in vitro assays suggest that E6 oncoprotein of HPV-
16 and -18 can bind and degrade the p53 protein. it is of
interest to determine whether or not a similar mechanism is
relevant to proteolysis for in vivo cervical cancer specimens.
As a result of the immunohistochemical analysis of p53
protein in the 45 HPV-positive cancers. we found that the
staining was inconsistent among the different cases. A
positive staining of p53 protein was recogised in ten cases.
The positivity of staining was not correlated with HPV copy
numbers. This indicates that the in vivo pS3 proteolysis is
regulated in a more complicated manner than in vitro. It has
been shown that the association of E6 with p53 protein is
mediated by an additional cellular factor. E6-AP (Huibregtse
et al.. 1991). Positive staining of the p53 protein could be
obtained in three of six HPV-negative cancers. Two out of
three of these positive cancers demonstrated the p53 muta-
tions. which was consistent with the increased stability of
mutant p53 proteins in the cells (Finlay et al.. 1988). How-
ever. case 7. which contained HPV type 16 DNA and a p53
mutation at amino acid residue 292. showed negative stain-
ing. The mutation at codon 292 resulted in an amino acid
substitution in the neighbourhood of the conserved regions
(Soussi et al.. 1987). This might not be associated with the
loss of the ability to be targeted for degradation by an E6
oncoprotein.
In the present study. three missense point mutations, which
give rise to altered p53 proteins, were documented at
amino acid residues 269. 273 and 292. Eleven of 12 muta-
tions that are involved in the present three cases as well as
the previously described nine cases (Paquette et al.. 1993)
were clustered between amino acid residues 130 and 290.
which are highly conserved among several different species
(Soussi et al.. 1987). The results are consistent with the
compiled data that described the position of point mutations
in the human p53 gene from various malignancies (Hollstein
et al.. 1991). and thus suggest the importance of this con-
served region for cervical cell carcinogenesis. A normal allele
was present in addition to a mutated allele in case 10 even
when only mutated alleles were observed in the remaining
two cases. It remains to be clarified whether the results of
case 10 indicate a heterozygous state or whether the presence
of either normal tissue or inflammatory cells within the
tumour sample is responsible for the apparent
heterozygosity.
References
ASAKAW A J. SATOH C. Y'AMASAKI Y' AND CHEN S. (1992).
Accurate and rapid detection of heterozygous camrers of a dele-
tion by combined polymerase chain reaction and high-per-
formance liquid chromatography. Proc. Natl .4cad. Sci. LSA. 89,
9126-9130.
BARBOSA MS. VASS WC. LOA'Y DR AND SCHILLER JT. (1991). In
vitro biological activities of the E6 and E7 genes vary among
human papillomaViruses of different oncogenic potential. J.
Virol.. 65, 292-298.
BEDELL MA. JONES KH. GROSSMAN SR AND LAIMINS LA. (1989).
Identification of human papillomavirus type 18 transforming
genes in immortalized and primary cells. J. Virol.. 63,
1247- 1'55.
CHEN TM. CHEN CA. HSIEH CY. CHANG DY. CHEN YH AND
DEFENDI V. (1993). The state of p53 in primary human cervical
carcinomas and its effects in human papillomavirus-immortalized
human cervical cells. Oncogene. 8, 1511-1518.
CROOK T AND VOUSDEN KH. (1992). Properties of p53 mutations
detected in primarv and secondary cervical cancers suggest
mechanisms of metastasis and involvement of environmental car-
cinogens. EMBO J.. 11, 3935-3940.
CROOK T. WREDE D AND VOUSDEN KH. (1991). p53 point muta-
tion in HPV negative human cervical carcinoma cell lines.
Oncogene. 6, 873-875.
CROOK T. WREDE D. TIDY' JA. MASON' WP. EVANS DJ AND
VOUSDEN KH. (1992). Clonal p53 mutation in primary cervical
cancer: association with human-papillomavirus-negative tumours.
Lancet. 339, 1070-1073.
DWORNICZAK B. AULEHLA-SCHOLZ C AND HORST J. (1990).
Phenylalanine hydroxylase gene: silent mutation uncovers evolu-
tionary ongin of different alleles. Clin. Genet.. 38, 270-273.
DYSON N. HOWLEY PM. MUN.GER K AND HARLOW E. (1989). The
human papilloma virus-16 E7 oncoprotein is able to bind to the
retinoblastoma gene product. Science. 243, 934-937.
FINLAY CA. HINDS PW. TAN TH. ELIYAHU D. OREN M AND
LEVINE AJ (1988). Activating mutations for transformation by
p53 produce a gene product that forms an hsc7O-p53 complex
with an altered half-life. Mol. Cell. Biol.. 8, 531-539.
FUCHS PG. GIRARDI F AND PFISTER H. (1989). Human papil-
lomavirus 16 DNA in cervical cancers and in lymph nodes of
cersical cancer patients: a diagnostic marker for early metastases?
Int. J. Cancer. 43, 41-44.
FUJINAGAY. SHIMADA M. OKAZAWA K. FUKUSHIMA M. KATO I
AND FUJINAGA K. (1991). Simultaneous detection and typing of
genital human papillomavirus DNA using the polymerase chain
reaction. J. Gen. Virol.. 72, 1039-1044.p53 lIpclbation in ceclc developinw_ *v K Mrwa et a
226
FUJITA M. INOUE M. TANIZAWA 0, IWAMOTO S AND ENOMOTO
T. (1992). Alterations of the p53 gene in human primary cervical
carcinoma with and without human papillomavirus infection.
Cancer Res.. 52, 5323-5328.
GOELZ SE, HAMILTON SR AND VOGELSTEIN B. (1985). Purification
of DNA from formaldehyde-fixed and paraffin-embedded human
tissue. Biochem. Biophks. Res. Commun.. 130, 118-126.
HAYASHI K, ORITA M. SUZUKI Y AND SEKIYA T. (1989). Use of
labeled primers in polymerase chain reaction (LP-PCR) for a
rapid detection of the product. Nucleic Acids Res.. 17, 3605.
HOLLSTEIN M. SIDRANSKY D, VOGELSTEIN B AND HARRIS CC.
(1991). p53 mutations in human cancers. Science, 253, 49-53.
HUIBREGTSE JM. SCHEFFNER M AND HOWLEY PM. (1991). A
cellular protein mediates association of p53 with the E6 onco-
protein of human papillomavirus types 16 or 18. EMBO J.. 10,
4129-4135.
KISHIMOTO Y. MURAKAMI Y. SHIRAISHI M, HAYASHI K AND
SEKIYA T. (1992). Aberrations of the p53 tumor suppressor gene
in human non-small cell carcinomas of the lung. Cancer Res.. 52,
4799-4804.
KWOK SCM. LEDLEY FD. DILELLA AG. ROBSON KJH AND WOO
SLC. (1985). Nucleotide sequence of a full-length complementary
DNA clone and amino acid sequence of human phenylalanine
hydroxylase. Biochemistry. 24, 556-561.
MOMAND J. ZAMBETTI GP. OLSON DC. GEORGE D AND LEVINE
AJ. (1992). The mdm-2 oncogene product forms a complex with
the p53 protein and inhibits p53-mediated transactivation. Cell.
69, 1237-1245.
MURAKAMI Y, HAYASHI K AND SEKIYA T. (1991). Detection of
aberrations of the p53 alleles and the gene transcript in human
tumour cell lines by single-strand conformation polymorphism
analysis. Cancer Res.. 51, 3356-3361.
MUNGER K. PHELPS WC. BUBB V. HOWLEY PM AND SCHLEGEL R.
(1989). The E6 and E7 genes of the human papillomavirus type
16 together are necessary and sufficient for transformation of
primary human keratinocytes. J. Virol., 63, 4417-4421.
OLINER JD. KINZLER KW. MELTZER PS. GEORGE DL AND
VOGELSTEIN B. (1992). Amplification of a gene encoding a p53-
associated protein in human sarcomas. Nature, 358, 80-83.
PAQUETTE RL. LEE YY. WILCZYNSKI SP. KARMAKAR A. KIZAKI
M. MILLER CW AND KOEFFLER HP. (1993). Mutations of p53
and human papillomavirus infection in cervical carcinoma.
Cancer. 72, 1272- 1280.
ROMAN A AND FIFE KH. (1989). Human papillomaviruses: are we
ready to type? Clin. Microbiol. Rev.. 2, 166-190.
SCHEFFNER M. MUNGER K. BYRNE JC AND HOWLEY PM. (1991).
The state of the p53 and retinoblastoma genes in human cervical
carcinoma cell lines. Proc. .%atl Acad. Sci. L'SA. 88,
5523-5527.
SOUSSI T. DE FROMENTEL CC. MECHALI M. MAY P AND KRESS
M. (1987). Cloning and characterization of a cDNA from
Xenopus laevis coding for a protein homologous to human and
murine p53. Oncogene. 1, 71-78.
VOJETSEK B. BARTEK J. MIDGLEY CA AND LANE DP. (1992). An
immunochemical analysis of human nuclear phosphoprotein p53:
new monoclonal antibodies and epitope mapping using recom-
binant p53. J. Immunol. Methods, 151, 237-244.
WERNESS BA. LEVINE AJ AND HOWLEY PM. (1990). Association of
human papillomavirus type 16 and 18 E6 proteins with p53.
Science. 248, 76-79.
ZUR HAUSEN H. (1987). Papillomaviruses in human cancer. Appl.
Pathol.. 5, 19-24.